Molecular mechanisms and drug therapy of metabolism disorders in psoriasis.
Yanyang LiangYing WangAihong PengJunqin LiKaiming ZhangPublished in: The Journal of dermatological treatment (2024)
In psoriasis, enhanced glycolysis, glutamine metabolism and altered fatty acid composition in the psoriatic lesion and plasma result in the excessive proliferation of keratinocytes and secretion of inflammatory cytokines. Altered metabolism is associated with the activation of MTORC signaling pathway and transcription factors such as HIF and S6K1. Therefore, MTORC1 can be a target for the treatment of psoriasis. Additionally, there are diabetes drugs and lipid-lowering drugs including TZDs, GLP-1 RAs, Metformin, statins and fibrates, which improve both metabolic levels and psoriasis symptoms.
Keyphrases
- signaling pathway
- fatty acid
- cardiovascular disease
- transcription factor
- atopic dermatitis
- type diabetes
- rheumatoid arthritis
- epithelial mesenchymal transition
- stem cells
- body mass index
- depressive symptoms
- endothelial cells
- bone marrow
- ankylosing spondylitis
- endoplasmic reticulum stress
- systemic lupus erythematosus
- cell proliferation
- replacement therapy
- dna binding
- cell therapy
- combination therapy